The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Status:
Terminated
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary
Arterial Hypertension (PAH) will increase exercise capacity. We also want to find out if
spironolactone and ambrisentan effect the cardiac output (amount of blood the heart pumps
every minute), right ventricle function and quality of life.